

**PATIENT INFORMATION**

NAME: \_\_\_\_\_  
LAST NAME FIRST NAME

ID/PASSPORT NO. \_\_\_\_\_ DATE OF BIRTH: \_\_\_\_/\_\_\_\_/\_\_\_\_  
DD MM YY

CLINICAL DIAGNOSIS: \_\_\_\_\_ GENDER  FEMALE  MALE

**SAMPLE INFORMATION**

DATE OF COLLECTION: \_\_\_\_/\_\_\_\_/\_\_\_\_ TIME: \_\_\_\_/\_\_\_\_  
DD MM YY HH MM

SAMPLE TYPE (Please select one) :

<input type="checkbox"/> Blood, Specify (EDTA, clotted)	<input type="checkbox"/> First Voided Urine
<input type="checkbox"/> Bone Marrow	<input type="checkbox"/> Stool
<input type="checkbox"/> EDTA Plasma	<input type="checkbox"/> Nasopharyngeal Aspirate/Swab
<input type="checkbox"/> Serum	<input type="checkbox"/> Autocyte/ThinPrep

Body Fluid, Specify Type: \_\_\_\_\_

Swab, Specify Type: \_\_\_\_\_

Tissue, Specify Type: \_\_\_\_\_

Paraffin Embedded Tissue, Specify Type: \_\_\_\_\_

Other, Please Specify: \_\_\_\_\_

**PATIENT CONSENT**

Confirmation of patient informed consent for genetic testing

**REPORTING INFORMATION**

PHYSICIAN: \_\_\_\_\_

INSTITUTION: \_\_\_\_\_

PHONE: \_\_\_\_\_ FAX: \_\_\_\_\_

SIGNATURE: \_\_\_\_\_ DATE (DD/MM/YY): \_\_\_\_\_

Please put a "✓" in the box(es) to indicate the test(s) to be performed.

**Oncology Testing**

- LUNG@MPD NGS Panel
- Lung Cancer Panel I (EGFR, ALK FISH & ROS1 FISH)
- Lung Cancer Panel II (BRAF, MET ex.14 skipping & ERBB2 ex.20)
- Lung Cancer Panel III (EGFR, ALK IHC & ROS1 FISH)
- COLON@MPD NGS Panel
- Colorectal Cancer Panel (KRAS, NRAS, BRAF & MSI)
- ACTION@MPD NGS Panel
- Brain Cancer Panel (MGMT Promoter Methylation & Chromosome 1p/19q Deletion)
- Endometrial Adenocarcinoma Classification Panel (POLE, MMR IHC & p53 IHC)
- BRCA1 & BRCA2 Gene Comprehensive Study
- KRAS & NRAS Gene Mutation Detection
- KIT & PDGFRA Gene Mutation Detection
- IDH1 & IDH2 Gene Mutation Detection
- MAP2K1 (MEK1) & MAP2K2 (MEK2) Gene Mutation Detection
- Microsatellite Instability Test & MMR Immunohistochemistry
- AKT1 codon 17 Mutation Detection
- ALK Gene Rearrangement Detection by FISH
- BRAF codon V600 Mutation Detection
- Breast Immunohistochemistry Panel (ER, PR, HER2 & Ki-67)
- Chromosome 1p/19q Deletion by FISH
- EGFR Gene Hotspot Mutation Detection (exons 18-21)
- EGFR Gene Amplification Detection by FISH
- ERBB2 exon 20 Mutation Detection
- ERBB2 (HER2) Gene Amplification by FISH | Fixation time  <6 hrs  6-72 hrs  >72 hrs
- ERBB2 (HER2) Immunohistochemistry
- ESR1 Gene Hotspot Mutation Detection (exon 5, 7 & 8)
- HRAS Gene Hotspot Mutation Detection (exons 2-4)
- HPV Detection and Genotyping (FFPE)  21 Genotypes  37 Genotypes
- KIT Gene Hotspot Mutation Detection (exon 9, 11, 13, 14 & 17)
- KRAS Gene Hotspot Mutation Detection (exons 2-4)
- MAPK1 E322K Mutation Detection
- MET exon 14 Skipping Mutation Detection
- MET Gene Amplification Detection by FISH
- MGMT Promoter Methylation by Methylation Specific PCR
- Microsatellite Instability Test
- MMR Immunohistochemistry
- NRAS Gene Hotspot Mutation Detection (exons 2-4)
- p53 Immunohistochemistry
- PALB2 Gene Comprehensive Study
- PDGFRA Gene Hotspot Mutation Detection (exon 12 & 18)
- PDL1 Immunohistochemistry  22C3  28-8
- PIK3CA Gene Hotspot Mutation Detection (exon 9 & 20)
- PIK3CA Gene Hotspot Mutation Detection [Extended] (exon 1, 2, 4, 7, 9 & 20)
- POLE Gene Hotspot Mutation Detection (exons 9-14)

**Oncology Testing (Cont.)**

- RET Gene Hotspot Mutation Detection (exon 5, 8, 10, 11, 13-16)
- RET Gene Rearrangement Detection by FISH
- ROS1 Gene Rearrangement Detection by FISH
- TERT Gene Promoter Mutation Detection

**Foundation Medicine / Oncotype**

- FOUNDATIONONE CDx (324 cancer-related genes)
- FOUNDATIONONE LIQUID CDx (324 cancer-related genes)
- FOUNDATIONONE HEME Tissue (406 (DNA) & 265 (RNA) cancer-related genes)
- Oncotype DX Breast Recurrence Score test
- Oncotype DX Colon Recurrence Score test

**Hereditary Cancer Screening**

- APC Gene Comprehensive Study
- BRCA1 & BRCA2 Gene Comprehensive Study
- BMPR1A Gene Comprehensive Study
- CDH1 Gene Mutation Detection
- CHEK2 1100delC Mutation Detection
- EPCAM Gene Deletion Study
- MLH1 Gene Comprehensive Study
- MMR Genes Promoter Methylation Detection
- MSH2 Gene Comprehensive Study
- MSH6 Gene Comprehensive Study
- MUTYH Gene Comprehensive Study
- PMS2 Gene Comprehensive Study
- PTEN Gene Comprehensive Study
- RET Gene Mutation Detection
- SLC25A13 Gene Mutation Detection
- STK11 Gene Comprehensive Study
- SMAD4 Gene Comprehensive Study
- TP53 Gene Comprehensive Study
- VHL Gene Comprehensive Study
- Hereditary Cancer Panel (84 cancer-related genes)

**Pharmacogenomics**

- CYP2C9 & VKORC1 Genotyping for Warfarin Treatment
- CYP2C19 Genotyping for Clopidogrel Treatment
- DPYD Genotyping for 5-FU Responsiveness
- HLA-B\*1301 Genotyping for Dapsone, Baklar or Phenytoin Treatment
- HLA-B\*1502 Genotyping for Carbamazepine Treatment
- HLA-B\*27 Genotyping
- HLA-B\*5801 Genotyping for Allopurinol Treatment
- NUDT15 Genotyping for Thiopurine Drugs Treatment
- TPMT Genotyping for Thiopurine Drugs Treatment
- UGT1A1 Genotyping for Irinotecan Toxicity

Others  Please Specify: \_\_\_\_\_

